Richard Pazdur

FDA Building
Pharma

2023 forecast: FDA revamps cancer drug approvals

SVB's Daina Graybosch foresaw a “massive delay” in cancer drug approvals as companies try to shift gear and adjust their regulatory timeline.
Angus Liu Dec 21, 2022 5:00am
topic report
Influential regulators and advocates

Most influential people in biopharma—the regulators and advocates

May 23, 2022 3:00am
Asia map globe

FDA oncology chief, Senate bill, Insilico—Fierce Pharma Asia

Apr 1, 2022 9:35am
FDA

FDA oncology czar defends rejection of Lilly-Innovent PD-1

Mar 28, 2022 11:34am
Lilly

Lilly promises 40% discount for PD-1, heaping pressure on FDA

Feb 10, 2022 11:45am
FDA Building

Lilly, Innovent's PD-1 faces tough FDA review

Feb 8, 2022 1:37pm